Secondary enucleated retinoblastoma with MYCN amplification

References

• Doz F, Peter M, Schleiermacher G, Vielh P, Validire P, Putterman M, Blanquet V, Desjardins L, Dufier J-L, Zucker J-M, et al. N-MYC amplification, loss of heterozygosity on the short arm of chromosome 1 and DNA ploidy in retinoblastoma. Eur J Cancer. 1996;32A(4):645–49. PMID:8695269. doi:10.1016/0959-8049(95)00626-5.
   PubMed Web of Science ®Google Scholar
• Kim JH, Choi JM, Yu YS, Kim DH, Kim JH, Kim K-W. N-myc amplification was rarely detected by fluorescence in situ hybridization in retinoblastoma. Hum Pathol. 2008;39(8):1172–75. PMID: 18538370. doi:10.1016/j.humpath.2007.12.008.
   PubMed Web of Science ®Google Scholar
• Lillington DM, Goff LK, Kingston JE, Onadim Z, Price E, Domizio P, Young BD, Richards-Yutz J, Shields CL, Eagle RC, et al. High level amplification of N-MYC is not associated with adverse histology or outcome in primary retinoblastoma tumours. Br J Cancer. 2002;87(7):779–82. PMID: 12232763. doi:10.1038/sj.bjc.6600532.
   PubMed Web of Science ®Google Scholar
• Ewens KG, Bhatti TR, Moran KA. Phosphorylation of pRb: mechanism for RB pathway inactivation in MYCN-amplified retinoblastoma. Cancer Med. 2017;6(3):619–30. PMID: 28211617. doi:10.1002/cam4.1010.
   PubMed Web of Science ®Google Scholar
• Rushlow DE, Mol BM, Kennett JY, Yee S, Pajovic S, Thériault BL, Prigoda-Lee NL, Spencer C, Dimaras H, Corson TW, et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol. 2013;14(4):327–34. PMID: 23498719. doi:10.1016/S1470-2045(13)70045-7.
   PubMed Web of Science ®Google Scholar
• Lee W-H, Murphree AL, Benedict WF. Expression and amplification of the N-myc gene in primary retinoblastoma. Nature. 1984; 309(5967):458–60. PMID: 6728001. doi:10.1038/309458a0.
   PubMed Web of Science ®Google Scholar
• Berry JL, Xu L, Kooi I, Murphree AL, Prabakar RK, Reid M, Stachelek K, Le BHA, Welter L, Reiser BJ, et al. Genomic cfDNA analysis of aqueous humor in retinoblastoma predicts eye salvage: the surrogate tumor biopsy for retinoblastoma. Mol Cancer Res. 2018;16(11):1701–12. PMID: 30061186. doi:10.1158/1541-7786.MCR-18-0369.
   PubMed Web of Science ®Google Scholar
• Tornoczky T, Semjen D, Shimada H. Pathology of peripheral neuroblastic tumors: significance of prominent nucleoli in undifferentiated/poorly differentiated neuroblastoma. Pathol Oncol Res. 2007;13(4):269–75. PAOR.2007.13.4.0269.PMID: 18158560.
   PubMed Web of Science ®Google Scholar
• Schwermer M, Hiber M, Dreesmann S, Rieb A, Theißen J, Herold T, Schramm A, Temming P, Steenpass L. Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines. Exp Cell Res. 2019;375(2):92–99. PMID: 30584916. doi:10.1016/j.yexcr.2018.12.018.
   PubMed Web of Science ®Google Scholar
• Wu N, Jia D, Bates B, Basom R, Eberhart CG, MacPherson D. A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence. J Clin Invest. 2017;127(3):888–98. PMID: 28165337. doi:10.1172/JCI88508.
   PubMed Web of Science ®Google Scholar
• Adams PD. Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. Biochim Biophys Acta. 2001;1471(3):M123–133. PMID: 11250068. doi:10.1016/s0304-419x(01)00019-1.
   PubMed Web of Science ®Google Scholar
• Rubin SM. Deciphering the retinoblastoma protein phosphorylation code. Trends Biochem Sci. 2013;38(1):12–19. PMID: 23218751. doi:10.1016/j.tibs.2012.10.007.
   PubMed Web of Science ®Google Scholar
• Antonucci LA, Egger JV, Krucher NA. Phosphorylation of the retinoblastoma protein (Rb) on serine-807 is required for association with Bax. Cell Cycle. 2014;13(22):3611–17. PMID: 25483096. doi:10.4161/15384101.2014.964093.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Okamoto S, Ishikawa Y, Tamura H, Hara T. DDX1 is required for testicular tumorigenesis, partially through the transcriptional activation of 12p stem cell genes. Oncogene. 2009;28(21):2142–51. PMID: 19398953. doi:10.1038/onc.2009.89.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Ikeda N, Miyashita K. DEAD box protein DDX1 promotes colorectal tumorigenesis through transcriptional activation of the LGR5 gene. Cancer Sci. 2018;109(8):2479–89. PMID: 29869821. doi:10.1111/cas.13661.
   PubMed Web of Science ®Google Scholar
• Weber A, Imisch P, Bergmann E. Coamplification of DDX1 correlates with an improved survival probability in children with MYCN-amplified human neuroblastoma. J Clin Oncol. 2004;22(13):2681–90. PMID: 15226335. doi:10.1200/JCO.2004.07.192.
   PubMed Web of Science ®Google Scholar
• Godbout R, Li L, Liu R-Z, Roy K. Role of DEAD box 1 in retinoblastoma and neuroblastoma. Future Oncol. 2007;3(5):575–87. PMID: 17927523. doi:10.2217/14796694.3.5.575.
   PubMedGoogle Scholar
• Dai -Q-Q, Wang -Y-Y, Jiang Y-P, Li L, Wang H-J. VSNL1 promotes gastric cancer cell proliferation and migration by regulating P2X3/P2Y2 receptors and is a clinical indicator of poor prognosis in gastric cancer patients. Gastroenterol Res Pract. 2020;2020:7241942. PMID: 3376484. doi:10.1155/2020/7241942.
   PubMed Web of Science ®Google Scholar
• Lee J-H, Park J-W, Byun JK, Kim HK, Ryu PD, Lee SY, Kim D-Y. Silencing of voltage-gated potassium channel KV9.3 inhibits proliferation in human colon and lung carcinoma cells. Oncotarget. 2015;6(10):8132–43. PMID: 25924237. doi:10.18632/oncotarget.3517.
   PubMedGoogle Scholar
• Asnaghi L, White DT, Key N, Choi J, Mahale A, Alkatan H, Edward DP, Elkhamary SM, Al-Mesfer S, Maktabi A, et al. ACVR1C/SMAD2 signaling promotes invasion and growth in retinoblastoma. Oncogene. 2019;38(12):2056–75. PMID: 30401983. doi:10.1038/s41388-018-0543-2.
   PubMed Web of Science ®Google Scholar
• Hook KE, Garza SJ, Lira ME, Ching KA, Lee NV, Cao J, Yuan J, Ye J, Ozeck M, Shi ST, et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther. 2012;11(3):710–19. PMID: 22222631. doi:10.1158/1535-7163.MCT-11-0184.
   PubMed Web of Science ®Google Scholar
• Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013;3(3):308–23. PMID: 23430699. doi:10.1158/2159-8290.CD-12-0418.
   PubMed Web of Science ®Google Scholar
• Vaughan L, Clarke PA, Barker K, Chanthery Y, Gustafson CW, Tucker E, Renshaw J, Raynaud F, Li X, Burke R, et al. Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget. 2016;7(36):57525–44. PMID: 27438153. doi:10.18632/oncotarget.10544.
   PubMedGoogle Scholar
• Zugbi S, Ganiewich D, Bhattacharyya A, Aschero R, Ottaviani D, Sampor C, Cafferata E, Mena M, Sgroi M, Winter U, et al. Clinical, genomic, and pharmacological study of MYCN-amplified RB1 wild-type metastatic retinoblastoma. Cancers (Basel). 2020;12(9):2714. PMID: 32971811. doi:10.3390/cancers12092714.
   Web of Science ®Google Scholar